Teva Pharmaceutical Industries Ltd. $TEVA Shares Acquired by Quantinno Capital Management LP

Quantinno Capital Management LP increased its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 13.3% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 216,461 shares of the company’s stock after purchasing an additional 25,349 shares during the quarter. Quantinno Capital Management LP’s holdings in Teva Pharmaceutical Industries were worth $6,520,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in TEVA. Legal & General Group Plc lifted its position in shares of Teva Pharmaceutical Industries by 6.8% in the fourth quarter. Legal & General Group Plc now owns 3,608,387 shares of the company’s stock valued at $112,618,000 after acquiring an additional 228,189 shares in the last quarter. Norges Bank purchased a new position in Teva Pharmaceutical Industries in the 4th quarter valued at about $1,098,060,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 8.0% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,082,578 shares of the company’s stock worth $33,506,000 after purchasing an additional 80,106 shares during the last quarter. TD Asset Management Inc grew its holdings in shares of Teva Pharmaceutical Industries by 47.1% during the fourth quarter. TD Asset Management Inc now owns 369,023 shares of the company’s stock worth $11,517,000 after buying an additional 118,075 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $9,126,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TEVA. Truist Financial raised their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Barclays increased their target price on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Piper Sandler lifted their price target on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday, July 28th. Finally, Weiss Ratings upgraded Teva Pharmaceutical Industries from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, July 31st. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Eliyahu Sharon Kalif sold 106,563 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the completion of the sale, the executive vice president owned 65,621 shares of the company’s stock, valued at approximately $2,237,676.10. The trade was a 61.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 0.9%

Shares of TEVA opened at $34.73 on Thursday. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $15.75 and a fifty-two week high of $37.35. The company’s fifty day moving average is $33.24 and its two-hundred day moving average is $32.78. The firm has a market cap of $39.94 billion, a PE ratio of 57.89, a price-to-earnings-growth ratio of 3.68 and a beta of 0.86. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. The business had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. Analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.96 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.